ClinicalTrials.gg
RecruitingNCT07599176Updated Oct 13, 2026

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

A Phase 1/2 interventional study of Total Body Irradiation and Alemtuzumab in Sickle Cell Disease and Beta-thalassemia, sponsored by National Heart, Lung, and Blood Institute (NHLBI). Recruiting at 1 site in United States. Open to participants aged 4 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by National Heart, Lung, and Blood Institute (NHLBI) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
4 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing alemtuzumab in Anemia, Sickle Cell — 6 open to participants now, 14 under way, none of them phase 3. Alemtuzumab · Anemia, Sickle Cell.

Planned enrollment
5th of 22
90 · median 44
Started
2026
with 1 other
Phase 1/2
5 of 22
2 open now
Primary completion
2032-06
later than 12 of 13 live
Registered
21st of 22
by date
Lead sponsor
4 of 22
National Heart, Lung, and Blood Institute (NHLBI)

Among the 22 studies testing alemtuzumab in Anemia, Sickle Cell, this one is the 5th largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 12 of the 13 other live ones, and was the 21st registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

6 of the 22 studies testing alemtuzumab in Anemia, Sickle Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

About alemtuzumab

Alemtuzumab: first FDA approval 2001 (LEMTRADA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 4 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing alemtuzumab in Anemia, Sickle Cell, or all of them as a file.
02

Study summary

This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher percentage of donor cells to stably remain in the recipients long term.

Read the detailed description

Study Description:

Our prior non-myeloablative conditioning regimen (03H0170) included 1mg/kg of alemtuzumab divided over 5 days, 300 cGy total body irradiation (TBI), and sirolimus for immune suppression. Sickle disease-free survival (DFS) and overall survival (OS) were 85% and 94% respectively, graft failure 15%, no transplant related mortality (TRM), and acute or chronic GVHD \<5%. A large proportion of patients achieved robust (>=95%) donor myeloid chimerism at day 30, but this proportion decreased quickly to 67.2% at 1, 64.9% at 2, and 60% at 3, and 56.9% at 4 years post-transplant.

A subsequent protocol (000539H) added briquilimab, an antibody targeting CD117 (c-Kit), to alem-300 cGy TBI regimen, but did not reduce the gradual decline in donor myeloid chimerism as originally hypothesized, leading to protocol closure. Rates of graft failure was 20%, no TRM, acute GVHD was 5%, and no chronic GVHD. We now propose to increase TBI to 400 cGy to further deplete host lymphoid and myeloid cells to achieve a higher percentage of donor leukocyte engraftment without substantially increasing toxicity. Since we will continue to use filgrastim to mobilize and collect donor hematopoietic cells, we also add abatacept to preserve the low rates of GVHD.

Objectives:

Primary Objective:

To reduce the proportion of patients with graft failure or donor myeloid chimerism \<95%

Secondary Objectives:

  • To compare CD14/15 and CD3 chimerism to prior MRD HCT protocols (03-H-0170, 14-H-0077, and 000539H)
  • To assess the usual transplant related parameters, such as count recovery, transfusion support, rates of GVHD, viral/bacterial infections, rates of transplant related and overall mortality, and compare to prior MRD HCT protocols

Tertiary Objectives:

  • To compare changes in organ function
  • To examine neuropsychological functioning, wellbeing, and pain before and after HCT
  • To obtain reproductive health related changes before and after HCT

Endpoints:

Primary Endpoint: proportion of participants with graft failure or myeloid chimerism \<95% at 1 year post HCT

Secondary Endpoints:

  • Percent myeloid (CD14/15) chimerism at day 30, 60, 100, 1 year, 2 years, and 3 years post HCT
  • Percent T cell (CD3) chimerism at day 30, 60, 100, 1 year, 2 years, and 3 years post HCT
  • Day of neutrophil engraftment per CIBMTR definition
  • Day of platelet engraftment per CIBMTR definition
  • Rates of viral reactivation or infection to day 100 post HCT
  • Rates of acute and chronic GVHD at 1 and 2 years post HCT, respectively
  • Rates of graft failure or myeloid chimerism \<95% at 1 year post HCT
  • Transplant related mortality at 1, 2, and 3 years post HCT
  • Non-transplant related mortality at 1, 2 and 3 years post HCT

Exploratory Endpoints:

-Quality of life, neuropsychologic function, reproductive health questionnaires, serial testing or imaging of organ function/status

03

Conditions studied

  • Sickle Cell Disease
  • Beta-thalassemia

Keywords

  • Sickle Cell Disease
  • Beta-Thalassemia
  • Stem Cell Transplant
  • Chimerism
04

Who can participate

Ages eligible
4 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

RECIPIENT:

Participants must fulfill one disease category (1 or 2) and 3

  1. Patients with sickle cell disease at high risk for disease related morbidity or mortality, defined by having an end-organ damage (A, B, C, D, OR E) or complication(s) not ameliorated by sickle cell-specific therapies (F):

    A. Stroke defined as a neurologic event that is accompanied by an infarct on cerebral MRI ORb

    B. Abnormal trans-cranial Doppler examination (>=200 cm/s); OR

    C. Silent cerebral infarct defined as an infarct-like lesion based on an MRI signal abnormality at least 3 mm in one dimension and visible in two planes on FLAIR or T2- weighted images (or similar image with 3D imaging) and documented neurological examination performed by a neurologist demonstrating the participant has a normal neurologic examination, or an abnormality on examination that could not be explained by the location of the brain lesion(s); OR

    D. Sickle cell related renal insufficiency defined by a creatinine level >=1.5 times the and kidney consistent with sickle cell nephropathy OR nephrotic syndrome OR \<60mL/min/1.73m2 for patients \<16 years of age or \<50mL/min for patients >16 years of age OR requiring peritoneal or hemodialysis; OR

    Age (Years): \<= 5 / Upper limit of normal serum creatinine (mg/dl): 0.8

    Age (Years): 5 \< age \<= 10 / Upper limit of normal serum creatinine (mg/dl): 1.0

    Age (Years): 10 \< age \<= 15 / Upper limit of normal serum creatinine (mg/dl): 1.2

    Age (Years): > 15 / Upper limit of normal serum creatinine (mg/dl): 1.3

    E. Tricuspid regurgitant jet velocity (TRV) of >=2.5 m/s in patients at least 3 weeks after a vaso-occlusive crisis; OR

    F. Recurrent severe priapism defined as at least two episodes of an erection lasting >=4 hours requiring medical intervention (e.g. aspiration, injection of vasoconstrictor, prior penile surgery.); OR

    G. Sickle hepatopathy defined as EITHER ferritin >1000mcg/L OR direct >0.4 mg/dL at baseline; OR

    H. Vaso-occlusive crises: more than 1 hospital admission per year while on a therapeutic dose of sickle cell treatment /medication; OR

    I. Acute chest syndrome (ACS): any ACS while on sickle cell treatment /medication

  2. Patients with beta-thalassemia who have grade 2 or 3 iron overload, determined by the presence of 2 or more of the following:

    • Portal fibrosis by liver biopsy
    • Inadequate chelation history (defined as failure to maintain adequate compliance with chelation with deferoxamine initiated within 18 months of the first transfusion and administered at least 5 days each week)
    • Hepatomegaly of greater than 2 cm below the costochondral margin or by other imaging scans
  3. Non disease specific

    • Ages >=4 years and less than 65 years old
    • Fully matched human leukocyte antigen (HLA) donors at A, B, C, and DR loci (8 of 8 or 10 of 10)
    • Ability to comprehend and willing to sign an , assent obtained from minors when applicable. Negative serum or urine beta-HCG, when applicable
    • Agree to use throughout the study and 3 months after abatacept or sirolimus administration.

      • Female subjects must agree to use a medically acceptable method of birth control such as oral contraceptive, intrauterine device, barrier and spermicide, or implant/injection from start of screening until is stopped.
      • Male subjects must agree to use effective contraception (including condoms) from start of screening until immunosuppression is stopped.

DONOR:

  • Fully matched human leukocyte antigen (HLA) donors at A, B, C, and DR loci (8 of 8 or 10 of 10) are intended for this study.
  • Donors age 4 or older and >=15 kg (or weight deemed acceptable by IR for line placement, DTM for apheresis, and pediatric consult service) eligible to donate hematopoietic stem cells, are eligible for this study.
  • Donors will be evaluated in accordance with existing Standard NIH Policies and Procedures for determination of eligibility and suitability for clinical donation. Donors will sign on a separate protocol, 20-H-0099 NHLBI standard of care protocol for the mobilization and collection of HSCs. Note that participation in this study is offered to all eligible donors, but is not required for a donor to make a stem cell donation, so it is possible that not all donors will enroll onto this study.

Exclusion criteria

EXCLUSION CRITERIA

RECIPIENT:

  • or Lanksy performance status of \<40
  • Diffusing capacity of carbon monoxide \<35% predicted: DLCO corrected for or KCO (corrected for lung volume). This criterion may be omitted in young children (e.g. near age 5) or other individuals who may have difficulty understanding or complying with instructions of testing.
  • Baseline oxygen saturation of \<85% or PaO2 \<70
  • : \<35% estimated by ECHO
  • Transaminases >5x for age
  • Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within one month prior to starting the conditioning regimen
  • Major anticipated illness or organ failure incompatible with survival from HCT
  • Pregnant or breastfeeding

DONOR:

  • Pregnant or breastfeeding
  • Cognitively impaired subjects
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Other
    Matched related donors

    Donors for patients

    Other: Research blood draw

  • Experimental
    Transplant recipients

    Patients with symptomatic sickle cell disease or beta-thalassemia

    Radiation: Total Body Irradiation · Drug: Alemtuzumab · Drug: Abatacept · Other: Research blood draw

Interventions

  • RadiationTotal Body Irradiation

    Total Body Irradiation 400 cGy

  • 1 mg/kg

  • 10 mg/kg x 6

  • OtherResearch blood draw

    About 5 tablespoons of blood will be collected from donors for research purposes.

06

What researchers measure

Primary outcomes

  1. Donor myeloid chimerism

    percentage of donor myeloid chimerism

    Time frame: 1 year

Secondary outcomes

  1. Donor CD3 chimerism

    percentage of donor myeloid chimerism

    Time frame: 1 year

  2. Overall survival

    percentage of patients surviving at 1 year

    Time frame: 1 year

  3. Acute Graft versus Host Disease

    percentage of patients with Grade 2-4 acute GVHD

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • NIH Clinical Center Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Individual participant data

Plan to share: No — We are planning to collect and report data as a group.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2032, 71 months after the start.

Of 37 phase 1/2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 222. This study's planned 71 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2026
First posted
May 20, 2026
StartActual
Jul 8, 2026
Primary completionEst.
Jun 30, 2032
CompletionEst.
Jun 30, 2035
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07599176
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Jul 8, 2026
Primary completion
Jun 30, 2032 (estimated)
Completion
Jun 30, 2035 (estimated)
Last update
Oct 13, 2026

Study contacts

Kelly S Norris, R.N.
Contact
kelly.norris@nih.gov
(301) 529-7104
John F Tisdale, M.D.
Contact
johntis@mail.nih.gov
(301) 402-6497
John F Tisdale, M.D.
principal investigator · National Heart, Lung, and Blood Institute (NHLBI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alemtuzumab · Abatacept

Start the discussion